Efficacy and safety of rituximab biosimilar (DRL_RI) versus MabThera <sup>®</sup> in low-tumor-burden follicular lymphoma: the FLINTER study

Authors

Pramod Reddy (ORCID: https://orcid.org/0000-0002-2554-9054)
Volha A. Kalenik
Y. Baranau (ORCID: https://orcid.org/0000-0003-4582-5615)
Ana Isabel Molina-Ramos (ORCID: https://orcid.org/0000-0002-0735-9417)
Dharma Rao Uppada (ORCID: https://orcid.org/0000-0002-4615-465X)
Anand Eswaraiah
Narendra Maharaj
David Belada (ORCID: https://orcid.org/0000-0002-4981-6188)
Jin Seok Kim (ORCID: https://orcid.org/0000-0001-8986-8436)
Ranjith Kakkattu

Institutions

Yonsei University (KR)
Severance Hospital (KR)
Dr. Reddy's Laboratories (India) (IN)
9th City Clinical Hospital (BY)
N.N. Alexandrov National Cancer Centre (BY)
Duran i Reynals Hospital (ES)

Publication Details

Journal: Therapeutic Advances in Medical Oncology
Published: 2025-01-01
DOI: https://doi.org/10.1177/17588359251339925
Primary Topic: Lymphoma Diagnosis and Treatment
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Efficacy and safety of rituximab biosimilar (DRL_RI) versus MabThera ^® in low-tumor-burden follicular lymphoma: the FLINTER study

Pramod Reddy, Volha A. Kalenik, Y. Baranau, Ana Isabel Molina-Ramos et al.

Jan 1, 2025

Therapeutic Advances in Medical Oncology

Lymphoma Diagnosis and Treatment

article

Efficacy and safety of rituximab biosimilar (DRL_RI) versus MabThera ^® in low-tumor-burden follicular lymphoma: the FLINTER study

Pramod Reddy, Volha A. Kalenik, Y. Baranau, Ana Isabel Molina-Ramos, Dharma Rao Uppada, Anand Eswaraiah, Narendra Maharaj, David Belada, Jin Seok Kim, Ranjith Kakkattu

January 1, 2025article en

Abstract

No abstract available for this paper.

Therapeutic Advances in Medical OncologyVol. 17

Yonsei University (KR), Severance Hospital (KR), Dr. Reddy's Laboratories (India) (IN), 9th City Clinical Hospital (BY), N.N. Alexandrov National Cancer Centre (BY), Duran i Reynals Hospital (ES)

Good health and well-being

Openalex Percentile: Top 84%

Lymphoma Diagnosis and Treatment

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Efficacy and safety of rituximab biosimilar (DRL_RI) versus MabThera <sup>®</sup> in low-tumor-burden follicular lymphoma: the FLINTER study — Pramod Reddy, Volha A. Kalenik, et al. · Therapeutic Advances in Medical Oncology (2025) | TGRS Research Map | TGRS